Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest

Summary

Deep Hypothermic Circulatory Arrest (DHCA) is employed during thoracic aortic and congenital heart surgery, and can induce postoperative neurological damage probably caused by microthrombembolism. Hypothermia has been reported to induce platelet activation and aggregation. The platelet activation marker P-selectin mediates binding of platelets to leukocytes. Tirofiban and eptifibatide, short-acting inhibitors of the platelet fibrinogen receptor GP IIb/IIIa, have recently been shown to protect platelet function without increasing bleeding during heart surgery using cardiopulmonary bypass. The aim of this study was to investigate the effect of tirofiban and eptifibatide on platelets and platelet-leukocyte interaction under DHCA conditions in vitro.Platelet aggregation, binding of the GP IIb/IIIa activation specific antibody PAC-1, P-selectin expression as well as monocyte and granulocyte content of aggregates were investigated in un-stimulated and ADP-stimulated samples using flow cytometry. Tirofiban and eptifibatide inhibited massive platelet aggregation and PAC-1 binding which were induced by DHCA conditions. P-selectin expression was inhibited by tirofiban but increased by eptifibatide at hypothermia. Platelet-bound leukocytes were present in all samples. Eptifibatide increased granulocyte content of aggregates at hypothermia in ADP-stimulated samples. We conclude that under conditions of DHCA both tirofiban and eptifibatide inhibit platelet aggregation but have different effects on platelet P-selectin expression and platelet-leukocyte interaction. Application of a short-acting and non-activating GP IIb/IIIa inhibitor should be considered during DHCA in vivo to prevent occlusion of the microvasculature and subsequent organ damage.

Keywords

Platelet physiology - cell-cell interactions - coagulation inhibitors - platelet pharmacology

• References

• 1 Ergin MA, Uysal S, Reich DL. et al. Temporary neurological dysfunction after deep hypothermic circulatory arrest: a clinical marker of long-term functional deficit. Ann Thorac Surg 1999; 67: 1887-90 discussion 1891–4.
• 2 Bellinger DC, Jonas RA, Rappaport LA. et al. Developmental and neurologic status of children after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass. N Engl J Med 1995; 332: 549-55.
• 3 Newburger JW, Jonas RA, Wernovsky G. et al. A comparison of the perioperative neurologic effects of hypothermic circulatory arrest versus low-flow cardiopulmonary bypass in infant heart surgery. N Engl J Med 1993; 329: 1057-64.
• 4 Jonas RA. Deep hypothermic circulatory arrest: Current status and indications. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2002; 5: 76-88.
• 5 Di Eusanio M, Wesselink RM, Morshuis WJ. et al. Deep hypothermic circulatory arrest and antegrade selective cerebral perfusion during ascending aortahemiarch replacement: a retrospective comparative study. J Thorac Cardiovasc Surg 2003; 125: 849-54.
• 6 Tassani P, Barankay A, Haas F. et al. Cardiac surgery with deep hypothermic circulatory arrest produces less systemic inflammatory response than low-flow cardiopulmonary bypass in newborns. J Thorac Cardiovasc Surg 2002; 123: 648-54.
• 7 Hall MW, Goodman PD, Alston SM. et al. Hypothermia- induced platelet aggregation in heparinized flowing human blood: identification of a high responder subpopulation. Am J Hematol 2002; 69: 45-55.
• 8 Faraday N, Rosenfeld BA. In vitro hypothermia enhances platelet GPIIb-IIIa activation and P-selectin expression. Anesthesiology 1998; 88: 1579-85.
• 9 Straub A, Azevedo R, Beierlein W. et al. Hypothermia induced platelet aggregation: no effect of aprotinin (trasylol) but inhibition by eptifibatide (integrilin). Thorac Cardiovasc Surg 2005; 53: 80-4.
• 10 Doré M. Platelet-leukocyte interactions. Am Heart J 1998; 135 (Suppl. 05) (Suppl. 02) S146-51.
• 11 Taylor KM. Brain damage during cardiopulmonary bypass. Ann Thorac Surg 1998; 65 (Suppl. 04) S20-6 discussion S27–8.
• 12 Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-31.
• 13 Schrör K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 2003; 15: 71-80.
• 14 Gretler DD. Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular weight heparin enoxaparin. Clin Ther 2003; 25: 2564-74.
• 15 Schneider DJ, Herrmann HC, Lakkis N. et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003; 91: 334-6.
• 16 Jy W, Horstman LL, Park H. et al. Platelet aggregates as markers of platelet activation: characterization of flow cytometric method suitable for clinical applications. Am J Hematol 1998; 57: 33-42.
• 17 Abrams CS, Ellison N, Budzynski AZ. et al. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75: 128-38.
• 18 Bartlett MS. The use of transformations. Biometrics 1947; 3: 39-52.
• 19 Holmes MB, Sobel BE, Schneider DJ. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. Am J Cardiol 1999; 84: 203-7.
• 20 Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc Res 2000; 45: 437-46.
• 21 Peter K, Schwarz M, Ylanne J. et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998; 92: 3240-9.
• 22 Yeo EL, Sheppard JA, Feuerstein IA. Role of P-selectin and leukocyte activation in polymorphonuclear cell adhesion to surface adherent activated platelets under physiologic shear conditions (an injury vessel wall model)1. Blood 1994; 83: 2498-507.
• 23 Davenpeck KL, Brummet ME, Hudson SA. et al. Activation of human leukocytes reduces surface P-selectin glycoprotein ligand-1 (PSGL-1, CD162) and adhesion to P-selectin in vitro . J Immunol 2000; 165: 2764-72.
• 24 Diacovo TG, Roth SJ, Buccola JM. et al. Neutrophil rolling, arrest, and transmigration across activated, surface- adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996; 88: 146-57.
• 25 Dore M. Platelet-leukocyte interactions. Am Heart J 1998; 135 5 (Suppl. 02) S146-51.
• 26 Koster A, Chew DP, Kuebler W. et al. Effects of tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass. Am J Cardiol 2003; 91: 346-7.
• 27 Straub A, Wendel HP, Azevedo R. et al. The GP IIb/ IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation. Eur J Cardiothorac Surg 2005; 27: 617-21.
• 28 Bizzarri F, Scolletta S, Tucci E. et al. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 122: 1181-5.
• 29 Dyke CM, Bhatia D, Lorenz TJ. et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Ann Thorac Surg 2000; 70: 866-71 discussion 871–2.
• 30 Hiramatsu Y, Gikakis N, Anderson 3rd HL. et al. Tirofiban provides ‘‘platelet anesthesia” during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 1997; 113: 182-93.